Recently, Beijing Shurui Robotics Co., Ltd. (hereinafter referred to as "Shurui Robotics") had its IPO application on the STAR Market accepted by the Shanghai Stock Exchange, marking the company's second attempt to enter the capital market. As the first company in China and the second globally to receive approval for a single-port laparoscopic surgical robot, Shurui Robotics carries the "domestic substitution" halo. Its prospectus discloses a 2025 revenue growth of over 330% year-on-year, and a 2.42 million euro order from a Spanish public hospital is hailed as a milestone in overseas expansion.
However, behind these impressive figures, the company has accumulated losses exceeding 500 million yuan over three years, with a capacity utilization rate below 50%. R&D investment has been shrinking, and the revenue structure is heavily reliant on one-time complete machine sales. Under the long-term financial assessment constraints of the STAR Market's fifth listing standard, significant uncertainties remain regarding whether Shurui Robotics can successfully navigate the commercial "valley of death."
Behind the High-Growth Data: Idle Capacity, Single Revenue Stream, and Insufficient Commercial Cash Flow
From a financial perspective, from 2023 to 2025, Shurui Robotics' revenue was 449,000 yuan, 18.6275 million yuan, and 81.3083 million yuan respectively, with a growth rate of over 330% in 2025. However, net profit attributable to the parent company was -191 million yuan, -195 million yuan, and -132 million yuan respectively. Non-GAAP net profit was -192 million yuan, -221 million yuan, and -179 million yuan respectively, resulting in accumulated losses exceeding 500 million yuan over three years. By the end of 2025, the company's retained earnings had reached -530 million yuan.
On the cash flow front, the net cash flow from operating activities from 2023 to 2025 was -214 million yuan, -195 million yuan, and -106 million yuan respectively, with total net operating cash outflows exceeding 515 million yuan over three years. The company remains in a continuous state of cash burn, and its current operating funds are primarily dependent on equity financing.
Looking at the business, Shurui Robotics' revenue structure is quite narrow. In 2025, revenue from single-port robots and supporting equipment accounted for as high as 78.03%, while the proportion from tool consumables, technology, and maintenance services was only 17.44% and 4.53% respectively.
The mature profit model for the surgical robot industry should rely on recurring purchases of consumables and maintenance services to build a cash flow moat. However, Shurui Robotics currently generates over 70% of its revenue from one-time complete machine sales. The growth rate of consumables revenue does not match the growth rate of installations. For example, in 2025, the number of installations increased by 450% year-on-year, but consumables revenue only grew by about 280%. This indirectly reflects a low clinical usage rate of installed equipment, with surgical volume growth falling short of expectations, and the business model's stickiness has not yet been established.
From production and sales data, the prospectus shows that Shurui Robotics has built a production line with an annual design capacity of 50 surgical robots. However, actual production and sales have fallen far short of expectations. In 2023, the company produced 12 units but had no external sales, with all 449,000 yuan in revenue coming from non-core activities like property leasing and parts sales.
In 2024, production increased to 25 units, but only 2 were sold, resulting in a production-to-sales ratio of just 8%. In 2025, the situation improved slightly, with production of 23 units and sales of 11 units, raising the production-to-sales ratio to 47.83%. However, this is still below 50%, meaning the company's production line is operating at a semi-idle state most of the time, making it impossible to achieve economies of scale.
The low capacity utilization rate is largely due to the fact that the single-port surgical robot market is still in its early cultivation stage. Compared to multi-port robots, which have decades of clinical accumulation and physician awareness, the learning curve for single-port procedures is longer, and hospitals are more cautious in their purchasing decisions. As of the date of the prospectus, Shurui Robotics has only achieved commercial installations in 19 top-tier tertiary hospitals in China, with a limited customer base.
For this IPO, the company plans to raise approximately 1.05 billion yuan, which will be used for surgical robot R&D projects, global marketing and service network construction, production base upgrade and construction, and supplementary working capital. Of this, 230 million yuan is earmarked for the production base upgrade project to enhance capacity and production automation. However, as mentioned earlier, the company's current annual capacity of 50 units is utilized at less than 50%. With existing capacity sitting idle, the necessity and rationality of investing heavily in upgrading and expanding capacity are questionable.
Looking at industry precedents, slow commercialization ramp-up is a common phenomenon. For example, Tianzhihang, which was also listed under the fifth standard, achieved revenue of 136 million yuan in 2020. The market generally expected rapid growth, but its revenue declined for three consecutive years thereafter, reaching only 119 million yuan in 2023, narrowly avoiding the delisting threshold. MEDBOT-B (02252.HK), after its Hong Kong listing in 2021, saw continuous revenue growth, but its 2025 revenue of 551 million yuan was still far below initial market expectations. This shows that the difficulty of commercializing surgical robot companies far exceeds expectations, and high growth rates are often unsustainable. Against this backdrop, the potential risks of the company's fundraising for expansion are self-evident.
Controversial Stock Option Pricing, Shrinking R&D, and Weak Pipeline Amidst Intense Competition
From an expense perspective, large share-based payments are a significant component of the company's losses during the reporting period, and their pricing fairness and reasonableness may be questionable. In 2023, the company granted 63.0308 million restricted shares to Xing Yuzhu, a director, executive deputy general manager, and CFO, corresponding to 1.8 million shares, at a purchase price of only 1.2606 million yuan, or approximately 0.7 yuan per share.
On the grant date, the fair value of the company's equity was approximately 83.3 yuan per share, corresponding to a total fair value of the equity instruments of 150 million yuan. The company recognized a one-time share-based payment expense of 149 million yuan. In other words, the company's core financial management personnel acquired company equity worth 150 million yuan at a cost of less than 1.3 million yuan, resulting in a paper gain of over 148 million yuan, representing a premium of over 117 times. Such a stark pricing difference is rare even among companies planning an IPO.
It is noteworthy that the equity incentive did not include performance conditions tied to the company's results, installation numbers, or revenue growth rate. During the same period, other senior executives, such as the Board Secretary and Deputy General Manager, also received equity at prices far below fair value through employee stock ownership platforms. The average annual share-based payment expense for key management personnel during the reporting period exceeded 20 million yuan. Against a backdrop of the company suffering sustained large losses and relying heavily on external investor financing for daily operations, the reasonableness and fairness of management acquiring massive equity at extremely low prices warrant further scrutiny.
On the R&D front, from 2023 to 2025, the company's R&D expenses were 112 million yuan, 110 million yuan, and 88.1678 million yuan respectively, showing a year-on-year decline. In 2025, the decrease was approximately 20%. The number of R&D personnel also shrank concurrently, from 109 at the end of 2023 and 110 at the end of 2024, to 87 at the end of 2025. Their proportion of total employees fell from 40.67% to 32.71%.
Obtaining approval for an innovative medical device is just the starting point for commercialization. Subsequent indication expansion, product iteration, and next-generation technology development all require continuous high-intensity investment. For instance, Intuitive Surgical, with its Da Vinci system having been on the market for over 20 years, still invests over $1 billion annually in R&D, accounting for more than 10% of its revenue. Domestic leader MEDBOT-B invested over 600 million yuan in R&D in 2025, a 15% year-on-year increase. In comparison, Shurui Robotics' decision to shrink its R&D efforts at the beginning of its commercialization phase inevitably raises concerns about its future technological reserves.
Looking at the product pipeline, the depth of Shurui Robotics' product portfolio is clearly insufficient. Currently, the only commercially available product is the SR-ENS-600 series single-port laparoscopic surgical robot, which primarily covers basic indications like urology, general surgery, and thoracic surgery. The upgraded SR-ENS-660 model, approved in March 2026, only offers minor improvements in operational precision and system stability. It is essentially an optimized version of the same generation of products and is unlikely to generate significant incremental market share. The 700 series product is still in the early R&D phase and has not yet entered clinical trials.
In comparison, competitors have much broader product portfolios. MEDBOT-B has formed a full product matrix covering multi-port and single-port, laparoscopy, orthopedics, and pan-vascular fields. Jingfeng Medical also has both multi-port and single-port product lines advancing simultaneously, covering a wider range of departments and able to meet the diverse needs of hospitals, thereby possessing stronger risk resistance capabilities.
In fact, the single-port laparoscopic surgical robot track is rapidly transitioning from an early blue ocean market to a red ocean of competition. On the international front, Intuitive Surgical's Da Vinci SP system was approved by the FDA in 2018. It has been deeply embedded in the market for nearly 8 years, accumulating vast clinical data and strong physician user stickiness, holding over 90% of the global single-port robot market share. Medical device giants like Medtronic and Johnson & Johnson are also investing in single-port technology, leveraging their strong channels and brand advantages to accelerate penetration.
Competition in the domestic market is also becoming increasingly intense. Since 2024, two domestic single-port robots, Jingfeng Medical's SP1000 and MEDBOT-B's SA1000, have been approved for market launch. Together with Shurui's SR-ENS-600, the domestic single-port track has formed a "three-way" stalemate. The three companies have similar technical routes, overlapping indications, and all target the same top-tier tertiary hospitals, setting the stage for a potential price war. According to industry information, the bidding price for domestic single-port robots has dropped from an initial over 8 million yuan to the 5-6 million yuan range, with some projects even seeing low prices of just over 4 million yuan.
In summary, although Shurui Robotics has achieved high revenue growth and opened a window for overseas markets with its single-port surgical robot, the company still faces significant pressure in its commercialization ramp-up. After listing on the capital market, there remains considerable uncertainty about whether it can sustainably supplement its cash flow, refine its profit model, and expand its market share.
Massive information and precise interpretation are all available on the Sina Finance APP.
Editor: Company Observation
Comments